Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.2250 (-4.2%) ($4.2250 - $4.4600) on Tue. Jan. 18, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.08% (three month average) | RSI | 30 | Latest Price | $4.2250(-4.2%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.8% a day on average for past five trading days. | Weekly Trend | AUTL declines -7.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(64%) IBB(60%) IBUY(57%) ARKG(53%) ARKK(53%) | Factors Impacting AUTL price | AUTL will decline at least -2.54% in a week (0% probabilities). VIXM(-41%) VXX(-34%) TLT(-23%) TIP(-22%) SHY(-22%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.54% (StdDev 5.08%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.95(-335.5%) | Resistance Level | $4.97 | 5 Day Moving Average | $4.48(-5.69%) | 10 Day Moving Average | $4.65(-9.14%) | 20 Day Moving Average | $4.97(-14.99%) | To recent high | -40% | To recent low | 0% | Market Cap | $221m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |